Logo image of TGTX

TG THERAPEUTICS INC (TGTX) Stock Fundamental Analysis

NASDAQ:TGTX - US88322Q1085 - Common Stock

29.445 USD
+0.68 (+2.35%)
Last: 8/22/2025, 8:00:02 PM
29.4 USD
-0.05 (-0.15%)
After Hours: 8/22/2025, 8:00:02 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to TGTX. TGTX was compared to 549 industry peers in the Biotechnology industry. TGTX has an average financial health and profitability rating. TGTX is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

TGTX had positive earnings in the past year.
TGTX had a negative operating cash flow in the past year.
In multiple years TGTX reported negative net income over the last 5 years.
In the past 5 years TGTX always reported negative operating cash flow.
TGTX Yearly Net Income VS EBIT VS OCF VS FCFTGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

TGTX's Return On Assets of 8.60% is amongst the best of the industry. TGTX outperforms 92.71% of its industry peers.
TGTX's Return On Equity of 21.87% is amongst the best of the industry. TGTX outperforms 96.36% of its industry peers.
TGTX's Return On Invested Capital of 12.78% is amongst the best of the industry. TGTX outperforms 95.26% of its industry peers.
Industry RankSector Rank
ROA 8.6%
ROE 21.87%
ROIC 12.78%
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
TGTX Yearly ROA, ROE, ROICTGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

TGTX has a Profit Margin of 13.31%. This is amongst the best in the industry. TGTX outperforms 92.90% of its industry peers.
Looking at the Operating Margin, with a value of 18.91%, TGTX belongs to the top of the industry, outperforming 94.90% of the companies in the same industry.
TGTX's Gross Margin of 86.96% is amongst the best of the industry. TGTX outperforms 89.98% of its industry peers.
TGTX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 18.91%
PM (TTM) 13.31%
GM 86.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
TGTX Yearly Profit, Operating, Gross MarginsTGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TGTX is still creating some value.
The number of shares outstanding for TGTX has been increased compared to 1 year ago.
Compared to 5 years ago, TGTX has more shares outstanding
The debt/assets ratio for TGTX is higher compared to a year ago.
TGTX Yearly Shares OutstandingTGTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
TGTX Yearly Total Debt VS Total AssetsTGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 5.34 indicates that TGTX is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 5.34, TGTX is doing good in the industry, outperforming 77.60% of the companies in the same industry.
A Debt/Equity ratio of 0.89 indicates that TGTX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.89, TGTX is doing worse than 76.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Altman-Z 5.34
ROIC/WACC1.29
WACC9.87%
TGTX Yearly LT Debt VS Equity VS FCFTGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 3.86 indicates that TGTX has no problem at all paying its short term obligations.
With a Current ratio value of 3.86, TGTX perfoms like the industry average, outperforming 44.26% of the companies in the same industry.
A Quick Ratio of 2.96 indicates that TGTX has no problem at all paying its short term obligations.
TGTX has a worse Quick ratio (2.96) than 63.02% of its industry peers.
Industry RankSector Rank
Current Ratio 3.86
Quick Ratio 2.96
TGTX Yearly Current Assets VS Current LiabilitesTGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

TGTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.33%.
The Revenue has grown by 30.96% in the past year. This is a very strong growth!
The Revenue has been growing by 364.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-38.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%325%
Revenue 1Y (TTM)30.96%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%92.13%

3.2 Future

The Earnings Per Share is expected to grow by 100.25% on average over the next years. This is a very strong growth
TGTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.77% yearly.
EPS Next Y467.07%
EPS Next 2Y254.51%
EPS Next 3Y157.23%
EPS Next 5Y100.25%
Revenue Next Year85.34%
Revenue Next 2Y60.65%
Revenue Next 3Y47.35%
Revenue Next 5Y38.77%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TGTX Yearly Revenue VS EstimatesTGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
TGTX Yearly EPS VS EstimatesTGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

TGTX is valuated quite expensively with a Price/Earnings ratio of 79.58.
Compared to the rest of the industry, the Price/Earnings ratio of TGTX indicates a rather cheap valuation: TGTX is cheaper than 90.71% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of TGTX to the average of the S&P500 Index (27.24), we can say TGTX is valued expensively.
The Price/Forward Earnings ratio is 16.73, which indicates a correct valuation of TGTX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TGTX indicates a rather cheap valuation: TGTX is cheaper than 93.81% of the companies listed in the same industry.
TGTX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.82.
Industry RankSector Rank
PE 79.58
Fwd PE 16.73
TGTX Price Earnings VS Forward Price EarningsTGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, TGTX is valued cheaply inside the industry as 91.80% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 51.64
TGTX Per share dataTGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

TGTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of TGTX may justify a higher PE ratio.
TGTX's earnings are expected to grow with 157.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.17
PEG (5Y)N/A
EPS Next 2Y254.51%
EPS Next 3Y157.23%

More info and screens

0

5. Dividend

5.1 Amount

TGTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TG THERAPEUTICS INC

NASDAQ:TGTX (8/22/2025, 8:00:02 PM)

After market: 29.4 -0.05 (-0.15%)

29.445

+0.68 (+2.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04/bmo
Earnings (Next)11-03 2025-11-03
Inst Owners63.19%
Inst Owner Change2.85%
Ins Owners9.74%
Ins Owner Change0.01%
Market Cap4.67B
Analysts78.67
Price Target42.55 (44.51%)
Short Float %16.37%
Short Ratio11.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-53.54%
Min EPS beat(2)-83.83%
Max EPS beat(2)-23.26%
EPS beat(4)1
Avg EPS beat(4)-15.86%
Min EPS beat(4)-83.83%
Max EPS beat(4)77.18%
EPS beat(8)4
Avg EPS beat(8)69.34%
EPS beat(12)6
Avg EPS beat(12)43.68%
EPS beat(16)8
Avg EPS beat(16)35.05%
Revenue beat(2)1
Avg Revenue beat(2)-3.03%
Min Revenue beat(2)-6.11%
Max Revenue beat(2)0.05%
Revenue beat(4)3
Avg Revenue beat(4)0.18%
Min Revenue beat(4)-6.11%
Max Revenue beat(4)6.12%
Revenue beat(8)7
Avg Revenue beat(8)35.09%
Revenue beat(12)8
Avg Revenue beat(12)17.26%
Revenue beat(16)10
Avg Revenue beat(16)22.77%
PT rev (1m)-1.85%
PT rev (3m)-1.85%
EPS NQ rev (1m)-7.07%
EPS NQ rev (3m)-35.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.31%
Revenue NQ rev (1m)1.01%
Revenue NQ rev (3m)-6.27%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.73%
Valuation
Industry RankSector Rank
PE 79.58
Fwd PE 16.73
P/S 10.29
P/FCF N/A
P/OCF N/A
P/B 16.9
P/tB 16.9
EV/EBITDA 51.64
EPS(TTM)0.37
EY1.26%
EPS(NY)1.76
Fwd EY5.98%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS2.86
BVpS1.74
TBVpS1.74
PEG (NY)0.17
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 8.6%
ROE 21.87%
ROCE 16.18%
ROIC 12.78%
ROICexc 24.32%
ROICexgc 24.32%
OM 18.91%
PM (TTM) 13.31%
GM 86.96%
FCFM N/A
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
F-Score3
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Debt/EBITDA 2.85
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 3.33
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.86
Quick Ratio 2.96
Altman-Z 5.34
F-Score3
WACC9.87%
ROIC/WACC1.29
Cap/Depr(3y)23.6%
Cap/Depr(5y)87.79%
Cap/Sales(3y)0.17%
Cap/Sales(5y)48.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%325%
EPS Next Y467.07%
EPS Next 2Y254.51%
EPS Next 3Y157.23%
EPS Next 5Y100.25%
Revenue 1Y (TTM)30.96%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%92.13%
Revenue Next Year85.34%
Revenue Next 2Y60.65%
Revenue Next 3Y47.35%
Revenue Next 5Y38.77%
EBIT growth 1Y-15.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year406.88%
EBIT Next 3Y125.16%
EBIT Next 5YN/A
FCF growth 1Y63.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.11%
OCF growth 3YN/A
OCF growth 5YN/A